title: Microarray and pathway analysis reveal distinct mechanisms underlying cannabinoid-mediated modulation of LPS-induced activation of BV-2 microglial cells.
abstract: Cannabinoids are known to exert immunosuppressive activities. However, the mechanisms which contribute to these effects are unknown. Using lipopolysaccharide (LPS) to activate BV-2 microglial cells, we examined how Δ(9)-tetrahydrocannabinol (THC), the major psychoactive component of marijuana, and cannabidiol (CBD) the non-psychoactive component, modulate the inflammatory response. Microarray analysis of genome-wide mRNA levels was performed using Illumina platform and the resulting expression patterns analyzed using the Ingenuity Pathway Analysis to identify functional subsets of genes, and the Ingenuity System Database to denote the gene networks regulated by CBD and THC. From the 5338 transcripts that were differentially expressed across treatments, 400 transcripts were found to be upregulated by LPS, 502 by CBD+LPS and 424 by THC+LPS, while 145 were downregulated by LPS, 297 by CBD+LPS and 149 by THC+LPS, by 2-fold or more (p≤0.005). Results clearly link the effects of CBD and THC to inflammatory signaling pathways and identify new cannabinoid targets in the MAPK pathway (Dusp1, Dusp8, Dusp2), cell cycle related (Cdkn2b, Gadd45a) as well as JAK/STAT regulatory molecules (Socs3, Cish, Stat1). The impact of CBD on LPS-stimulated gene expression was greater than that of THC. We attribute this difference to the fact that CBD highly upregulated several genes encoding negative regulators of both NFκB and AP-1 transcriptional activities, such as Trib3 and Dusp1 known to be modulated through Nrf2 activation. The CBD-specific expression profile reflected changes associated with oxidative stress and glutathione depletion via Trib3 and expression of ATF4 target genes. Furthermore, the CBD affected genes were shown to be controlled by nuclear factors usually involved in regulation of stress response and inflammation, mainly via Nrf2/Hmox1 axis and the Nrf2/ATF4-Trib3 pathway. These observations indicate that CBD, and less so THC, induce a cellular stress response and that this response underlies their high immunosuppressant activities.
authors: The Dr. Miriam and Sheldon G. Adelson Center for the Biology of Addictive Diseases, Sackler Faculty of Medicine, Physiology and Pharmacology Department, Tel Aviv University, Tel Aviv, Israel.
authors: Ana
authors: A
authors: Juknat
authors: Maciej
authors: M
authors: Pietr
authors: Ewa
authors: E
authors: Kozela
authors: Neta
authors: N
authors: Rimmerman
authors: Rivka
authors: R
authors: Levy
authors: Fuying
authors: F
authors: Gao
authors: Giovanni
authors: G
authors: Coppola
authors: Daniel
authors: D
authors: Geschwind
authors: Zvi
authors: Z
authors: Vogel
mesh_terms: D000818:Animals; D002186:Cannabinoids / Q000494:pharmacology*; D002460:Cell Line; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000187:drug effects; D053263:Gene Regulatory Networks; D008070:Lipopolysaccharides / Q000494:pharmacology*; D051379:Mice; D017628:Microglia / Q000187:drug effects* / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D015203:Reproducibility of Results; D015398:Signal Transduction
chemical_list: D002186:Cannabinoids; D008070:Lipopolysaccharides; D012333:RNA, Messenger
references: Br J Clin Pharmacol. 2013 Feb;75(2):323-33
references: 22625422
references: J Biol Chem. 2010 Jan 15;285(3):1616-26
references: 19910459
references: Immunobiology. 2010 Aug;215(8):598-605
references: 19457575
references: Neuron. 2006 Jan 5;49(1):67-79
references: 16387640
references: Br J Pharmacol. 2012 Apr;165(8):2436-49
references: 21449981
references: BMC Neurosci. 2010 Mar 26;11:44
references: 20346144
references: J Biol Chem. 2011 Dec 23;286(51):43855-43870
references: 22030398
references: J Neuroimmunol. 2006 Nov;180(1-2):71-87
references: 16996144
references: Glia. 2000 Jan 1;29(1):58-69
references: 10594923
references: Nature. 2005 Oct 13;437(7061):1032-7
references: 16136080
references: Br J Pharmacol. 2011 Aug;163(7):1507-19
references: 21449980
references: Immunopharmacology. 1998 Nov;40(3):179-85
references: 9858061
references: Trends Pharmacol Sci. 2009 Oct;30(10):515-27
references: 19729208
references: FASEB J. 2002 Jan;16(1):61-71
references: 11772937
references: Nat Protoc. 2009;4(1):44-57
references: 19131956
references: Annu Rev Med. 2006;57:553-74
references: 16409166
references: J Neuroimmune Pharmacol. 2006 Mar;1(1):50-64
references: 18040791
references: Phytother Res. 2009 May;23(5):597-602
references: 18844286
references: Dialogues Clin Neurosci. 2007;9(4):413-30
references: 18286801
references: Neuropharmacology. 2012 Oct;63(5):776-83
references: 22659086
references: Immunology. 2008 Nov;125(3):344-58
references: 18422969
references: CNS Neurosci Ther. 2011 Dec;17(6):637-44
references: 20875047
references: FASEB J. 2006 Mar;20(3):515-7
references: 16384912
references: J Neuroinflammation. 2005 Feb 24;2(1):7
references: 15730561
references: Science. 2003 Jun 6;300(5625):1574-7
references: 12791994
references: Adv Enzyme Regul. 2003;43:121-34
references: 12791387
references: Nat Immunol. 2006 Mar;7(3):274-83
references: 16474395
references: Free Radic Biol Med. 2011 Sep 1;51(5):1054-61
references: 21238581
references: Chem Biodivers. 2007 Aug;4(8):1678-92
references: 17712814
references: Glia. 2010 Jul;58(9):1017-30
references: 20468046
references: Nat Genet. 2000 May;25(1):25-9
references: 10802651
references: Curr Opin Investig Drugs. 2007 May;8(5):373-84
references: 17520866
references: Proc Natl Acad Sci U S A. 2006 May 16;103(20):7895-900
references: 16672367
references: J Biol Chem. 2004 Oct 8;279(41):42703-8
references: 15299019
references: Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9561-6
references: 10920191
references: Glia. 2012 Jul;60(7):1182-90
references: 22535572
references: Br J Pharmacol. 2012 Apr;165(8):2512-28
references: 21542829
references: Neuromolecular Med. 2005;7(1-2):37-50
references: 16052037
references: Handb Exp Pharmacol. 2005;(168):385-423
references: 16596782
references: J Clin Invest. 2003 Sep;112(6):872-82
references: 12975472
references: J Neuroimmune Pharmacol. 2010 Mar;5(1):103-21
references: 19847654
references: J Neuroimmunol. 2004 Feb;147(1-2):91-4
references: 14741435
references: J Biol Chem. 2005 Sep 16;280(37):32485-92
references: 16000310
references: Pharmacol Ther. 2002 Aug;95(2):165-74
references: 12182963
references: J Biol Chem. 2003 Jul 18;278(29):27072-9
references: 12736262
references: Adv Nutr. 2012 May 01;3(3):307-21
references: 22585904
references: Nat Immunol. 2011 Jul 19;12(8):715-23
references: 21772280
references: Expert Rev Mol Med. 2009 Jan 20;11:e3
references: 19152719
references: Carcinogenesis. 2010 Aug;31(8):1319-28
references: 20106901
references: Nat Rev Cancer. 2012 May 04;12(6):436-44
references: 22555283
references: Mutat Res. 2010 Aug 7;690(1-2):12-23
references: 19799917
references: J Med Chem. 1997 Sep 26;40(20):3228-33
references: 9379442
references: Acta Neuropathol. 2010 Jan;119(1):89-105
references: 20012873
references: Nat Rev Cancer. 2003 Oct;3(10):745-55
references: 14570037
references: J Lipid Res. 2008 Apr;49(4):880-92
references: 18187772
references: Br J Pharmacol. 2008 Jan;153(2):240-51
references: 18037916
references: Pharmacol Ther. 2012 Jan;133(1):79-97
references: 21924288
references: FEBS Lett. 2009 Jun 18;583(12):2071-6
references: 19464294
references: Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11514-9
references: 9326641
references: Neurochem Int. 2012 Nov;61(6):923-30
references: 22178458
references: J Neuroimmunol. 1998 Mar 15;83(1-2):116-23
references: 9610679
references: Nat Rev Neurol. 2010 Jul;6(7):405-10
references: 20531383
references: Cancer Res. 2009 Jun 15;69(12):4945-7
references: 19509234
references: Eur J Pharmacol. 2009 Jun 10;612(1-3):61-8
references: 19285060
references: Am J Physiol Cell Physiol. 2006 Aug;291(2):C195-202
references: 16624989
references: Br J Pharmacol. 2007 Nov;152(5):576-82
references: 17704824
references: Mol Cell Biol. 1999 Jul;19(7):4798-805
references: 10373529
references: Nat Rev Immunol. 2011 Oct 25;11(11):775-87
references: 22025055
references: Cell Death Dis. 2012 Jun 28;3:e331
references: 22739983
references: Cell Mol Neurobiol. 2011 Aug;31(6):921-30
references: 21533611
references: Pharmacol Rev. 2010 Dec;62(4):588-631
references: 21079038
references: Ann N Y Acad Sci. 2007 Jan;1096:70-7
references: 17405917
references: Nat Rev Cancer. 2007 May;7(5):357-69
references: 17446857
references: EMBO J. 2005 Mar 23;24(6):1243-55
references: 15775988
references: PLoS One. 2011;6(12):e28668
references: 22163051